ALVR | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 3%

Liquidity 50%

Performance 10%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

5.13%

1 Month

-12.52%

3 Months

-40.79%

6 Months

-39.35%

1 Year

-32.33%

2 Year

-90.06%

Key data

Stock price

$0.47

P/E Ratio

0.00

DAY RANGE

$0.46 - $0.47

EPS

$0.00

52 WEEK RANGE

$0.46 - $1.05

52 WEEK CHANGE

-$30.41

MARKET CAP

89.904 M

YIELD

N/A

SHARES OUTSTANDING

115.365 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.42

PUBLIC FLOAT

AVERAGE 10 VOLUME

$340,540

AVERAGE 30 VOLUME

$320,895

Company detail

CEO: Diana M. Brainard
Region: US
Website: allovir.com
Employees: 110
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies. The company's lead product is posoleucel, which is an allogenic off the shelf VST therapy. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19.

ALVR - Allovir, Inc.